Amy Hay is an experienced leader in setting strategy, negotiating transactions and implementingglobal oncology programs. Her expertise lies within identifying synergistic relationships thatprovide value and her portfolio has ranged from working with health systems, governments,corporations, providers and industry leaders worldwide.In April 2021, Siemens Healthineers acquired Varian and Amy has been leading integration teams within the oncology workstream to ensure synergies across both organizations are identified and targets are exceeded in commercial acceleration and platform expansion. Today Amy is responsible for the strategic initiatives and the deployment of “Oncology as a Service” (OaaS), which aggregates medical technology, clinical solutions and technology enabled services globally. Set by her strategy, Varian has built out technology enabled solutions that span virtual tumor boards and molecular analytics. Within her first year, she closed a partnership with Ayala Health in the Philippines and CHRISTUS Health in the US, providing cumulative revenues of more than $75M. Amy joined Varian through the acquisition of her consulting company, Evolve International, in January of 2020. Evolve provided strategic consulting to healthcare providers, not-for-profit organizations, health related startups and big data technology companies such as the Eliminate Cancer Initiative in Australia, M2GEN at the Moffitt Cancer Center, City of Hope, Nano and the Cancer Commons.As the Senior Vice President, Network Development, at The University of Texas MD Anderson Cancer Center (MDACC), Amy Hay was a member of the Chief Operating Officer’s senior leadership team. She was instrumental in setting the institutional strategy for expansion, inclusive of 7 branded partners and 16 quality assurance members, which grew nationally across 19 states, 22 systems, and 48 hospitals, impacting more than 46,000 new cancer cases in 2016.